Study: Risperidone as Antimanic Monotherapy
use of mood stabilizers in combination with risperidone, have been shown to be effective for the treatment of acute mania. However, this study tries to find and assess the effects of risperidone as an antimanic when given alone in patients with acute mania. In another sentence that this research is to find an answer whether risperidone can be effective as monotherapy in treating acute mania.
The research was conducted in the United States for 3 weeks, with a random sample, double-blind, placebo-controlled trial, multicenter. The size of primary efficacy was mean change from baseline in Young Mania Rating Scale (YMRS) total score. A total of 262 patients were included in this study, 134 samples at random to patients with acute mania risperidone and 128 samples are given with a placebo. As many as 56% of patients assigned to risperidone and 42% of placebo patients completed the study. The most common reason for discontinuation in the placebo group was sufficient response (36%), and withdrawal of approval in the risperidone group (16%). Patients with acute mania treated with risperidone showed significant improvements in YMRS score at 3 days and each subsequent time point. After 3 weeks of treatment, YMRS scores decreased 5 points in the placebo group vs. 11 points in the risperidone group (P <.001). And the use of risperidone was associated with the effects of adding a mild weight gain (1.6 kg after 3 weeks) and side effects somnolence.
Overall, risperidone can significantly improved the prognosis of acute mania immediately on treatment day 3, and risperidone provide improvements that persist for a 3-week study period. On the Montgomery-Asberg penilaiannilai by their Depression Rating Scale score, risperidone not only improved the prognosis of acute mania, but also risperidone improve prognosis of depression in patients with bipolar disorder. This study further showed that risperidone can be safely used as monotherapy or in combination with mood stabilizers in the treatment of acute mania.
Study About Treatment of Acute Mania: Olanzapine Vs Lithium
In this study, the authors conducted a meta-analysis method of randomized controlled trials to compare the effectiveness of lithium with olanzapine as monotherapy for the treatment of acute mania both in patient with bipolar disorders, symptoms of manic with psychotic feature or other. Although there is no doubt that lithium is an effective drug in the treatment of acute mania, 'side effects and latency' a relatively long time until the optimal effect (about 2 weeks), somewhat limiting its use in the treatment of acute mania. The author in his research looking for MEDLINE (1996-2003) and identified seven randomized trials with use of lithium and 6 studies with the use of olanzapine for the treatment of acute mania. A total of 178 patients who received treatment with lithium for an average of 3.6 weeks of treatment and 728 patients who received treatment with olanzapine for an average of 4.3 weeks of treatment included in the analysis. Overall, the researchers concluded that olanzapine is as effective drugs in the treatment of acute mania as lithium, and has a faster onset than treatment with lithium.
No comments:
Post a Comment